Peri- and postoperative outcomes of robot-assisted radical cystectomy (RARC)
Article first published online: 14 SEP 2011
© 2011 THE AUTHORS. BJU INTERNATIONAL © 2011 BJU INTERNATIONAL
Volume 108, Issue 6b, pages 969–975, September 2011
How to Cite
Smith, A. B., Raynor, M. C. and Pruthi, R. S. (2011), Peri- and postoperative outcomes of robot-assisted radical cystectomy (RARC). BJU International, 108: 969–975. doi: 10.1111/j.1464-410X.2011.10456.x
- Issue published online: 14 SEP 2011
- Article first published online: 14 SEP 2011
- Accepted for publication 4 May 2011
- radical cystectomy;
- bladder neoplasm;
- urothelial carcinoma;
What's known on the subject? and What does the study add?
Robot-assisted radical cystectomy is an increasingly used method for surgical extirpation for clinically localized, muscle-invasive urothelial cartinoma. This study reviews its technique and associated preoperative and oncological outcomes.
- • To assess peri-and postoperative outcomes of robot-assisted radical cystectomy (RARC) with pelvic lymph node dissection (PLND) and urinary diversion for the treatment of bladder cancer.
MATERIALS AND METHODS
- • We review our previously described surgical technique for RARC and its development over recent years, with an accompanied video illustration.
- • We also focus on peri- and postoperative outcomes of RARC and compare this with the ‘gold standard’ of open RC.
- • RARC has been steadily growing since 2003, with acceptable peri-and postoperative outcomes.
- • Most studies report decreased blood loss, return of bowel function, and shorter length of hospital stay. Furthermore, complication rates have been shown to be similar to that of open series.
- • Most importantly, oncological outcomes appear to be favourable in terms of margin status, LND and disease-specific survival, although data may be affected by the lack of long-term results and a randomized clinical trial assessing overall survival.
- • RARC with PLND and urinary diversion is an increasingly used strategy in the treatment armamentarium for bladder cancer.
- • Perioperative and oncological outcomes from existing data have been favourable thus far, but are limited by relatively short follow-up.
- • Randomized clinical trials with extended patient follow-up are needed to fully assess outcomes related to RARC.